Dr Reddy's Laboratories Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 800% at ₹8/Share	10-Jul-2026	10-Jul-2026
DividendsFinal Dividend of 800% at ₹8/Share	10-Jul-2025	10-Jul-2025
Stock Split1:5	28-Oct-2024	28-Oct-2024

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Parag Parikh Flexi Cap Fund - Regular Plan - Growth	1.43 Cr	1.45 Cr (1.11%)
SBI Nifty 50 ETF	1.18 Cr	1.18 Cr (0.04%)
ICICI Prudential Value Fund - Growth	93.47 Lac	95.69 Lac (2.38%)
ICICI Prudential India Opportunities Fund - Growth	78.45 Lac	78.45 Lac no change
ICICI Prudential Large Cap Fund - Growth	62.98 Lac	63.19 Lac (0.35%)

Vimal K

12 Oct • 11:20 PM · SEBI-Registered Analyst

Nifty Outlook for 13-Oct-2026 Looks Bearish

On Monday Nifty opened stronger at 22,593.20, hitting an intraday high of 22,651.10. However, persistent selling pressure and profit booking at higher levels caused a complete intraday reversal. Nifty gave up all early gains to close 0.70% lower at 22,363.35. The Daily MACD Histogram and Hourly MACD Histogram below zero indicates a bearish trend. The Daily RSI 14 below 40 and Hourly RSI 14 also below 40 indicates a bearish trend. Thus the overall trend of Nifty looks bearish, and the sellers are in control over the markets. Sell on rise would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains above the resistance level. Can Initiate buying only if prices continue to sustain above the resistance level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 22455 Resistance 2 - 22485 Support 1 - 22215 Support 2 - 22170 Happy Learning, Happy Trading and have a wonderful day. Top Gainers : DRREDDY, BAJAJ AUTO, TMPV.

DRREDDY

Hemraj Singh Sikarwar

12 Oct • 9:50 PM · SEBI-Registered Analyst

Dr Reddy's Lab: Why is the stock outperforming the market?

While the broader Indian market ended lower on Monday, Dr. Reddy's Laboratories Limited

DRREDDY

moved in the opposite direction. The stock gained 2.71% on October 12 to close at ₹1,229.40, making it the top Nifty 50 gainer of the session. The Nifty 50, meanwhile, declined 0.70% to 22,363.35. What makes this interesting? The pharmaceutical sector can sometimes demonstrate relative resilience when investors reduce exposure to more economically sensitive businesses. However, one session of outperformance is not enough to establish a sustained trend. Three factors I would examine 1. US business performance The US generics market remains important for Indian pharmaceutical companies. Pricing pressure, product launches and competition can influence profitability. 2. Product pipeline New launches and regulatory approvals can support future growth, but their commercial contribution needs to be assessed against development costs and competition. 3. Earnings quality Revenue growth is only one part of the story. Operating margins, cash generation and management guidance will help determine whether the current valuation is justified. Reading today's price action Dr. Reddy's relative strength is worth monitoring, particularly when the benchmark index is under pressure. But I would not assume that the stock is undervalued simply because it has risen while the market has fallen. The next step is to assess whether the business fundamentals support continued outperformance. My view Constructive on the relative strength, but awaiting confirmation from earnings and business developments before taking a stronger directional view. What I am watching: US sales trends, product launches, pricing pressure and operating margins. Research disclosure:. I do not hold Dr. Reddy's Laboratories Limited]. This post represents an independent research opinion based on publicly available information and is not personalised investment advice.

Shree Dhanraksha Securities

12 Oct • 8:30 PM · SEBI-Registered Analyst

Regulatory development can influence pharmaceutical Industry

Pharmaceutical Sector : Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories

DRREDDY

came under investor scrutiny after receiving an FDA Form 483 containing two observations following an inspection of its Andhra Pradesh facility. A Form 483 identifies observations made by the US Food and Drug Administration during an inspection; it is not, by itself, a final regulatory determination. Investors should follow the company's response, any corrective actions and subsequent regulatory developments. Pharmaceutical-stock analysis should also include product approvals, generic-drug competition, research expenditure, export exposure and manufacturing quality. Learning takeaway: Regulatory developments can influence pharmaceutical companies, but investors must distinguish inspection observations from final regulatory outcomes.

Hruthik N

12 Oct • 4:53 PM · SEBI-Registered Analyst

Dr Reddy’s Gains 2.7% as Sensex Falls 548

The market closed lower today, reversing an early rally. The Sensex fell 547.65 points (0.76%) to 71,924.68, and the Nifty fell 157.10 points (0.70%) to 22,363.35. The Nifty opened at 22,593.20 and hit a high of 22,651.10 but slid to a low of 22,304.45. Selling in IT, FMCG and financial stocks drove the fall. Oil eased and the RBI’s steps to support the rupee gave some relief, but foreign outflows, higher bond yields and earnings worries kept investors cautious. 1)

DRREDDY

was the top Nifty gainer, rising 2.71% to ₹1,229.40. I couldn’t find a specific news trigger, so the move looks like defensive buying on a weak day. 2)Bajaj Auto and Tata Motors Passenger Vehicles also did well. Bajaj Auto gained 2.62% to ₹10,034, and TMPV rose 1.63% to ₹284.45. BEL and BSE Ltd were also among the top gainers. 3)The biggest losers: Apollo Hospitals fell over 3%, with ITC, Tech Mahindra, L&T, Hindalco and HUL also among the worst. ITC’s drop follows its sharp bounce on Friday. 4)Breadth was weak on the Sensex. At midday only 5 of its 30 stocks were advancing, so the damage was spread across the large caps. 5)Broader markets held up better. Midcap and smallcap indices ended higher even as the headline indices fell.

Mayank Kumar

11 Oct • 8:11 PM · SEBI-Registered Analyst

Dr. Reddy’s Laboratories is a major Indian pharmaceutical

DRREDDY

Dr. Reddy’s Laboratories is a major Indian pharmaceutical company with a diversified presence in generic medicines, branded formulations, active pharmaceutical ingredients (APIs), and international markets. One important recent development is that the US FDA issued a Form 483 with two observations following an inspection of the company’s FTO-11 manufacturing facility in Andhra Pradesh from October 5–7, 2026; this is a regulatory concern that investors should monitor, although observations alone do not establish a final compliance failure. The company is scheduled to announce its Q2 FY27 results on October 23, 2026, which will be an important trigger for the stock, particularly for revenue growth, profit margins, US business performance, and management commentary. Overall, its established pharmaceutical portfolio and global presence are important strengths, while regulatory developments, pricing pressure, and profitability trends remain key risks. The upcoming results may provide further clarity on its financial performance. For educational purposes only; not investment advice.

MBA Investmentwala

10 Oct • 11:37 AM · SEBI-Registered Analyst

Dr. Reddy’s Receives Two USFDA Observations

Dr. Reddy’s Laboratories

DRREDDY

Laboratories

DRREDDY

has received two observations in a USFDA Form 483 following a Pre-Approval Inspection (PAI) at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. USFDA Inspection Details The inspection was conducted from October 5 to October 7, 2026. Following the inspection, the US Food and Drug Administration issued Form 483 containing two observations. - Facility: FTO-11 manufacturing unit - Location: Pydibhimavaram, Andhra Pradesh - Inspection type: Pre-Approval Inspection (PAI) - Observations: 2 - Company response: Dr. Reddy’s said it will address the observations within the stipulated timeline. What Does Form 483 Mean? - A Form 483 records conditions that USFDA investigators believe may violate regulatory requirements. Receiving observations does not automatically mean that a facility has been declared non-compliant or that manufacturing has been suspended. - The company has not disclosed the specific nature of the two observations in its regulatory filing. - Their implications will depend on the issues identified and the company's response. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their risk profile before making any investment decision.

Dr. Reddy's Laboratories Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Dr. Reddy's Laboratories Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Dr. Reddy's Laboratories Ltd.?

What is the market cap of Dr. Reddy's Laboratories Ltd.?

Should I buy Dr. Reddy's Laboratories Ltd. stock now?

What is the 52 week high and low of Dr. Reddy's Laboratories Ltd.?

Is the Dr. Reddy's Laboratories Ltd. stock good to buy?

Is Dr. Reddy's Laboratories Ltd. a good buy for the long term?

Is Dr. Reddy's Laboratories Ltd. overvalued or undervalued?

What is the PE and PB ratio of Dr. Reddy's Laboratories Ltd.?